Engineered immune cells take aim at stubborn solid tumors
NCT ID NCT07672483
First seen Jun 29, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This trial tests a new approach for people with solid tumors that have returned or not responded to standard treatments. The therapy uses the patient's own myeloid cells, a type of immune cell, which are genetically modified in a lab to produce a cancer-fighting protein called IL-12. After a short course of chemotherapy to prepare the body, the modified cells are infused back into the patient. The goal is to see if these cells can safely attack tumors and at what dose they work best.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IL-12 GEMys (genetically engineered myeloid cells)
What this could lead to
If it works, this could point toward a new treatment for hard-to-treat solid tumors by using the body's own immune cells to fight cancer.
What could go wrong
This is an early phase 1 trial with a small number of participants, so safety and effectiveness are not yet proven. The treatment involves chemotherapy and cell infusion, which carry risks like infection and organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED SOLID TUMOR MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••